Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KARISMA: intravenous cipargamin in severe Plasmodium falciparum malaria
2020-005035-70Phase 2
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cipargamin in malaria and severe malaria (2 arms), sponsored by Novartis. Primary endpoint: Proportion of participants with at least 90% P. reduction.
02
Drugs
cipargamin
03
Conditions
malariasevere malaria
Beyond the preview
Go deeper on 2020-005035-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005035-70.